Evidence check: Östradiol in the context of longevity

The role of estradiol (17β-estradiol) in longevity is complex and not fully resolved. Estradiol is a key sex hormone that provides cardiovascular and cognitive protection in premenopausal women. After menopause, its sharp decline is linked to increased risks of osteoporosis, cardiovascular disease, and neurodegeneration. Some observational studies suggest that a longer reproductive lifespan (later menopause) correlates with greater life expectancy. However, effects are dose- and context-dependent: high estradiol levels raise the risk of breast cancer, endometrial cancer, and thrombosis. In men, elevated estradiol is associated with metabolic disturbances and reduced lifespan. The evidence base is largely epidemiological and mechanistic; randomized long-term longevity trials are lacking. Consumer hormone tests provide snapshots, not clinical diagnoses, and should not guide self-administered hormone therapy. Hormone replacement therapy requires medical supervision weighing benefits and risks. Overall, evidence is mixed: plausible mechanisms exist, but strong human evidence for direct lifespan extension via estradiol is absent.